CanSino Biologics Releases 2024 Annual Results

Story Highlights
  • CanSino Biologics focuses on vaccine development in the biopharmaceutical industry.
  • The company announced its audited annual results for 2024, ensuring transparency and compliance.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
CanSino Biologics Releases 2024 Annual Results

CanSino Biologics, Inc. Class H ( (HK:6185) ) has issued an update.

CanSino Biologics Inc. has announced its audited consolidated annual results for the year ending December 31, 2024. The results, which comply with the Hong Kong Stock Exchange’s listing requirements, have been reviewed and confirmed by the company’s board and audit committee. The annual report will be available to shareholders and on relevant websites, reflecting the company’s commitment to transparency and regulatory compliance.

More about CanSino Biologics, Inc. Class H

CanSino Biologics Inc. is a biotechnology company based in China, primarily focused on the development and production of innovative vaccines. It operates within the biopharmaceutical industry, targeting global markets with its vaccine products.

YTD Price Performance: 9.05%

Average Trading Volume: 1,343,043

Technical Sentiment Signal: Sell

Current Market Cap: HK$10.4B

For detailed information about 6185 stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App